Article
Author contributions G.N., C.D.M. and A.B. conceived the study. G.N., C.D.M. and A.E.
designed the experiments. G.N. and M.M. performed the majority of co-immunoprecipitation
and the in vitro experiments involving RagC. A.E. performed experiments involving FBS, RHEB
and TSC2, TFEB chimaera and Lys- and Mit-RAPTOR. C.D.M. and A.Z. performed the
experiments on FLCN-knockout HeLa cells, and generated and characterized the mouse lines
described in the study. D.S. was involved in the characterization of mouse lines and analysis of
RagA-knockout cells. C.V. was involved in some experiments on FLCN-knockout cells. E.N.
helped with mouse handling. V.B. and A.V. performed some of the experiments involving
Lys–RAPTOR. M.C. was involved in virus and cell line preparation. J.M. generated CRISPR–Cas9
gene-edited cell lines and performed some microscopy experiments. A.C. was involved in
some of the experiments related to RHEB depletion. M.E.G.d.A., T.S. and L.A.H. performed and
analysed biochemistry experiments. S.P., G.B. and P.P.D.F. performed and analysed histology
experiments. G.N., C.D.M. and A.B. wrote the manuscript. A.B. supervised the study.
Competing interests A.B. is cofounder of CASMA Therapeutics, Inc.Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41586-020-
2444-0.
Correspondence and requests for materials should be addressed to A.B.
Peer review information Nature thanks Kun-Liang Guan and the other, anonymous, reviewer(s)
for their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permissions information is available at http://www.nature.com/reprints.